Seres Therapeutics Reports Q1 Loss, Short Cash Runway, Awaits Key Clinical Data Amid Funding Search

summarizeSummary

Seres Therapeutics reported a Q1 net loss and a short cash runway through Q3 2026, intensifying its search for funding, while awaiting key clinical data for its SER-155 program.

check_boxKey Events

• Q1 Financial Results Show Net Loss

  The company reported a net loss of $19.9 million for the first quarter of 2026, a significant decline from a net income of $32.7 million in the same period of 2025, largely due to the absence of a $50 million payment from Nestlé.

• Shortened Cash Runway

  As of March 31, 2026, Seres had $29.8 million in cash and cash equivalents and expects to fund operations only through the third quarter of 2026, highlighting an urgent need for additional capital.

• Key Clinical Data Expected Soon

  A clinical readout from an investigator-sponsored study evaluating SER-155 in immune checkpoint inhibitor-related enterocolitis (irEC) is anticipated in the coming weeks, representing a potential near-term catalyst.

• Funding Sought for SER-155 Phase 2

  The SER-155 program for the prevention of bloodstream infections in allo-HSCT patients is Phase 2 ready, but the company is actively seeking funding to commence the study.

auto_awesomeAnalysis

Seres Therapeutics reported a net loss of $19.9 million for Q1 2026, a significant reversal from the prior year's net income, primarily due to the absence of a $50 million payment from Nestlé. The company's cash and cash equivalents stood at $29.8 million as of March 31, 2026, with an anticipated cash runway only through the third quarter of 2026. This short runway, following a previous going concern warning, underscores the urgent need for additional capital and partnerships to advance its pipeline. While the financial situation is challenging, the company anticipates a clinical readout from an investigator-sponsored SER-155 study in immune checkpoint inhibitor-related enterocolitis in the coming weeks, which could serve as a critical near-term catalyst.